Healthcare
Guggenheim Securities continues to provide healthcare clients with independent insight and expertise across the biopharma, medical devices, and healthcare services sectors. Our full-service firm includes a leading healthcare investment banking franchise, trusted as a long-term, strategic advisor, as well as capital markets solutions and a research department that performs deep primary research and generates actionable ideas.
Video Highlights
Opportunities in Healthcare Technology for Private Equity
Senior Managing Director David Blais, Healthcare Services Investment Banking, interviews Senior Managing Director Jon Pritti, Private Equity Advisory Group, to discuss the dynamics behind and opportunities around private equity’s focus on healthcare technology.
The Century Project: Living a Longer and Healthier Life
Healthcare Equities Sales Specialist Whitney Wolfe interviews Head of Equities Stefano Natella to discuss insights and highlights from 'The Century Project,' a series of reports that analyzes health factors influencing longevity and healthspan.
Healthcare Equities Sales Specialist Whitney Wolfe interviews Senior Managing Director of Healthcare Investment Banking Punit Mehta to discuss his outlook for M&A across the healthcare industry.
Representative Transactions in Healthcare
.svg)
.svg)
.svg)
.svg)
Social Media
LinkedIn: Barron's
Michael Schmidt's Research Featured In Barron's Article
Biotechnology Equity Research Analyst Michael Schmidt's research was featured in a Barron's article focusing on the recent spate of publicly announced biotech M&A transactions. The article highlighted names of oncology-focused companies that could be potential M&A targets in 2024.
.jpg)
LinkedIn: INI Conference
Guggenheim Thanks Participants and Attendees of INI Conference
Guggenheim Securities, LLC would like to thank the participants and attendees of the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference, hosted by the firm's healthcare equity research analysts.
The Century Project: Living a Longer and Healthier Life
Healthcare Equities Sales Specialist Whitney Wolfe interviews Head of Equities Stefano Natella to discuss insights and highlights from “The Century Project,” a series of reports that analyzes health factors influencing longevity and healthspan.
LinkedIn: CNBC
Punit Mehta Joins CNBC's 'Squawk on the Street'
Senior Managing Director Punit Mehta joins CNBC's "Squawk on the Street" to discuss his outlook for healthcare M&A.
Whitney Wolfe and Punit Mehta Discusses Healthcare M&A Outlook
Healthcare Equity Sales Specialist Whitney Wolfe interviews Senior Managing Director Punit Mehta, Healthcare Investment Banking, to discuss his outlook for M&A across the healthcare industry.
LinkedIn: Relievant Medsystems
Guggenheim Congratulates Relievant Medsystems, Inc. on its Transaction
Guggenheim Securities, LLC congratulates Relievant Medsystems, Inc. in connection with its $850 million (plus additional contingent payments) sale to Boston Scientific. Guggenheim served as the exclusive financial advisor to Relievant.
LinkedIn: WSJ
Vamil Divan Speaks With Wall Street Journal
Global Biopharmaceutical and Biotechnology Equity Research Analyst Vamil Divan, MD, MBA spoke with Peter Loftus of The Wall Street Journal about the effects of the recent business revamp by one of the world's largest healthcare companies.
LinkedIn: Ryan Lindquist
Guggenheim Hires Ryan Lindquist to Expand Healthcare Investment Banking Practice
Guggenheim Securities, LLC announced today that Ryan Lindquist has joined the firm as a Senior Managing Director in its Healthcare Investment Banking practice, where he will focus on diagnostics and life science tools.
LinkedIn: Sleep
Stefano Natella and Seamus Fernandez Talk With CNBC About Sleep
Head of Equities Stefano Natella and Global Biopharmaceuticals Equity Research Analyst Seamus Fernandez spoke with Michelle Fox at CNBC about the impacts of sleep deprivation and the development of sleep management drugs.
LinkedIn: Palette Life Sciences
Guggenheim Congratulates Palette Life Sciences on its Sale to Teleflex
Guggenheim Securities, LLC congratulates Palette Life Sciences in connection with its $600 million (plus up to $50 million in commercial milestones) sale to Teleflex. Guggenheim served as the exclusive financial advisor to Palette.
LinkedIn: Corevitas
Guggenheim Congratulates CorEvitas, LLC, on its Transaction
Guggenheim Securities, LLC congratulates CorEvitas, LLC, in connection with its $912.5 million sale to Thermo Fisher Scientific. Guggenheim served as a financial advisor to CorEvitas, LLC, a portfolio company of Audax Private Equity.
LinkedIn: Evan Wang
Evan Wang Expands Coverage of Healthcare Stocks
Evan Wang, Healthcare Equity Research Analyst covering Global Biopharmaceuticals and Biotechnology, recently increased Guggenheim Securities' Healthcare Research footprint by expanding coverage in the infectious disease and liver sectors.
LinkedIn: Zoetis
Guggenheim Congratulates Zoetis on its Transaction
Guggenheim Securities, LLC, congratulates Zoetis in connection with the sale of Pumpkin to JAB HOLDING COMPANY LLC.
LinkedIn: Guggenheim Securities
Guggenheim Thanks Attendees and Participants of Radiopharmaceuticals Day
Guggenheim would like to thank the participants and attendees of the Guggenheim Healthcare Talks Radiopharmaceuticals Day.
LinkedIn: #InnovationDublin23
Jennie Xue Participates in Panel at Innovation Summit Dublin
Senior Managing Director Jennie Xue, Medical Devices Investment Banking, participated in a panel at #InnovationDublin23, to provide her perspective on the current state of the medical devices M&A environment.
LinkedIn: Rare Disease Days
Guggenheim Thanks Attendees of Genomic Medicines and Rare Disease Days
Guggenheim would like to thank the participants and attendees of the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days.
LinkedIn: Healthcare Research
Vamil Divan Launches Healthcare Stock Coverage
Vamil Divan, MD, MBA, Healthcare Equity Research Analyst covering the Global Biopharmaceutical and Biotechnology sectors, expanded Guggenheim Securities’ Healthcare Research footprint in late February by launching coverage on nine healthcare stocks.
LinkedIn: Oncology Conference
Guggenheim Thanks Attendees of Oncology Day
Guggenheim would like to thank the participants and attendees of the Guggenheim Healthcare Talks 2023 Oncology Conference.
LinkedIn: Medisund
Guggenheim Congratulates Medusind on its Transaction
Guggenheim Securities, LLC congratulates Medusind, a portfolio company of H.I.G. Capital, in connection with its announced sale to Alpine Investors.
LinkedIn: Bloomberg
What Top Dealmakers Expect to See This Year in Health-Care M&A
Senior Managing Directors Punit Mehta and David Blais shared their views on the M&A outlook in healthcare with Michelle Davis from Bloomberg News.
LinkedIn: Summit Health
Guggenheim Congratulates Summit Health-CityMD on its Transaction
Guggenheim Securities, LLC congratulates Summit Health-CityMD, a portfolio company of Warburg Pincus LLC, in connection with its definitive agreement to be acquired by VillageMD, an affiliate of Walgreens Boots Alliance. Guggenheim served as a financial advisor to Summit Health-CityMD on its transaction.
LinkedIn: CNBC Closing Bell: Overtime
Seamus Fernandez Joins CNBC To Discuss Biopharmaceuticals
Biopharmaceutical Analyst Seamus Fernandez provides insight on CNBC Closing Bell: Overtime into his recent report on MRK.
LinkedIn: Immunology & Neurology Conference
Guggenheim Thanks Attendees of Immunology and Neurology Conference
Guggenheim would like to thank the presenters and attendees of the Immunology and Neurology Conference.
LinkedIn: Therapeutics Conference
Guggenheim Thanks Attendees of Therapeutics Conference
Guggenheim would like to thank the participants and attendees of the Therapeutics Conference.
LinkedIn: I&I Spotlight Series
I&I Spotlight Series - Treg-based Therapies
Senior Healthcare Sales Specialist Whitney Wolfe interviews Biotechnology Research Analyst Yatin Suneja on the rapid innovation of Tregs for the treatment of autoimmune diseases and diseases of the nervous system.
LinkedIn: I&I Spotlight Series
Guggenheim Thanks Attendees of I&I Spotlight Series
Guggenheim would like to thank the participants and attendees of the I&I Spotlight Series on Treg-based Therapies.
LinkedIn: Radiopharmaceutical Day
Guggenheim Thanks Attendees of Radiopharmaceutical Day
Guggenheim would like to thank the participants and attendees of Radiopharmaceutical Day.
LinkedIn: Synthetic Lethality Day
Guggenheim Thanks Attendees of Synthetic Lethality Day
Guggenheim would like to thank the participants and attendees of Synthetic Lethality Day
LinkedIn: Genomic Medicines & Rare Disease Day
Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day
At Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day, we provided healthcare clients with access to industry leadership in the constantly evolving sector.
LinkedIn: Targeted Protein Degradation Day
Highlights From the Second Guggenheim Targeted Protein Degradation Day
Equity Research Analyst Michael Schmidt, who covers biotech, provides highlights from our Targeted Protein Degradation Day, a part of the Guggenheim Healthcare Talks series, on March 16.
LinkedIn: Oncology Conference
Guggenheim Thanks Oncology Conference Attendees
Guggenheim would like to thank the participants and attendees of the Oncology Conference
LinkedIn: Biopharma Perspectives
Guggenheim Securities Healthcare - Biopharma Perspectives
At Guggenheim Securities, LLC we provide biopharmaceutical clients with independent insight and advice. As we survey 2022, we are sharing summaries of some of our most compelling thematic reports from the past year.
To access more information related to Healthcare at Guggenheim Securities, contact GSInfo@guggenheimpartners.com.
Important Notices and Disclosures
The information and materials provided herein (the “materials”) are provided for informational and educational purposes only and should not be considered a recommendation of any particular security, strategy or investment product, as investing advice of any kind, or as offering or providing any investment product or service, or as an offer or solicitation with respect to the purchase or sale of any investment by Guggenheim Securities, LLC or any of its affiliates (“Guggenheim”). The materials are not provided in an advisory or fiduciary capacity and may not be relied upon for or in connection with the making of investment decisions. The views expressed herein are solely those of the authors and may differ from the views of other officers, directors, employees or other representatives (as to any person or entity, its “Representatives”) of Guggenheim. The authors’ opinions are subject to change without notice. Guggenheim undertakes no obligation to provide additional information or any update to or correction of the information provided herein. Sources for the information contained herein are believed to be reliable, but the information is not guaranteed as to, and Guggenheim and its Representatives make no representation or warranty regarding, accuracy or completeness of any information contained herein or otherwise. Neither Guggenheim nor its Representatives shall be liable to any person in any way whatsoever for any losses, costs or claims for reliance on the materials. Guggenheim may have a business relationship with certain issuers mentioned herein, or may otherwise underwrite, hold a position, buy or sell as principal in the securities of any issuer mentioned. Guggenheim may have in the past provided, may currently be providing and may in the future seek to provide investment banking, financial advisory and other services to, and have other material relationships with, the issuers of securities, loans and other financial instruments referred to herein and their affiliates. With respect to any position Guggenheim may hold, Guggenheim may have interests different from or adverse to your interests. None of the materials provided may be reproduced or redistributed, in whole or in part, to any other person or published in whole or in part for any purpose absent the written consent of Guggenheim. By accessing or reviewing this website, you will be deemed to have acknowledged and agreed to the matters set forth above.
Copyright © 2023 by Guggenheim Securities, LLC, a FINRA registered broker-dealer. All rights reserved.